[go: up one dir, main page]

WO2012173469A1 - Diagnostic du cancer - Google Patents

Diagnostic du cancer Download PDF

Info

Publication number
WO2012173469A1
WO2012173469A1 PCT/NL2012/050406 NL2012050406W WO2012173469A1 WO 2012173469 A1 WO2012173469 A1 WO 2012173469A1 NL 2012050406 W NL2012050406 W NL 2012050406W WO 2012173469 A1 WO2012173469 A1 WO 2012173469A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
peptide
hydroxylation
peptides
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2012/050406
Other languages
English (en)
Inventor
Theo Marten Luider
Johannes Nicolaas Maria IJZERMANS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus University Medical Center
Original Assignee
Erasmus University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center filed Critical Erasmus University Medical Center
Priority to EP12728843.9A priority Critical patent/EP2721055A1/fr
Publication of WO2012173469A1 publication Critical patent/WO2012173469A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Definitions

  • the present invention is directed to diagnosis of cancer. More specifically to the diagnosis and/or prognosis of cancer by determining the hydroxylation pattern of a peptide from a biological sample from an organism.
  • Cancer is a leading cause of death worldwide and accounted for 7.6 million deaths (around 13% of all deaths) in 2008. Although the five-year survival rate for cancer increases each year, it varies much among the different types of cancer going from less than 2% five-year survival rate to more than 95% five- year survival rate.
  • pancreas, lung, oesophagus, stomach, brain, multiple myeloma, leukemia, kidney, rectum and colon cancer have a five-year survival rate of less than 50%.
  • prostate, larynx, bladder, melanoma, Hodgkin's lymphoma, testis, breast, uterus and cervix cancer have a five-year survival rate of more than 50%.
  • a diagnostic method for cancer is easy to use, may be performed on a biological sample that is easily obtained from an organism, is not expensive, has a broad coverage of the types of cancer and is applicable in many labs.
  • the present invention has at least one of the above objectives.
  • the present invention is directed to a method for diagnosing cancer by determining the hydroxylation pattern in a peptide from a biological sample from an organism.
  • WO2010/031822 discloses diagnosis of kidney cell carcinoma by detecting at least 3 peptides markers in a urine sample wherein the peptide markers are selected from table 1 describing 517 peptides only characterized by their mass and migration time. Table 3 shows a long list of peptide sequences however does not indicate hydroxylation. There is nothing in WO2010/031822 that points to hydroxylation of the peptide markers let alone to the use of the hydroxylation pattern for detecting cancer.
  • the present invention is directed to a method for diagnosing cancer by determining the hydroxylation pattern in a peptide in a biological sample from an organism. It was found that for different cancer types, peptides showed different hydroxylation patterns.
  • the present inventors realised, for the first time, that the simple detection of a hydroxylation pattern, i.e. whether a certain amino acid is hydroxylised or not, provides information on the type of cancer and also whether the cancer is primary or a secondary cancer. It is to be understood that the present invention is different then merely using a hydroxylised peptide as a biomarker. The present invention goes further. For the first time it is shown that the hydroxylation pattern, rather than a hydroxylised peptide, provides information on a cancer.
  • the term diagnosing includes determining whether an organism has cancer or not. It is to be understood that under diagnosis, in addition the indication of a stage or prognosis of a cancer in an organism is included. Prognosis relates to an opinion on how cancer will develop and/or how the cancer will influence other health condition and/or death/survival of the organism. Evidently, it is not always possible to diagnose with absolute certainty whether an organism has cancer by any method available presently, and this may also be true for the method of the invention.
  • diagnosing in the present invention also includes determining diagnosis cancer by determining the hydroxylation pattern in a peptide in a biological sample with a certain specificity of at least 50% or at least 60%, more preferable with a higher specificity such as 62%, 65%, 70%, 72%, 75%, 77%, 80%, 82%, 85%, 87%, 90%, 91%, 93%, 95%, 96%, 97%, 98%, 99% and most preferably 100%.
  • hydroxylation pattern is used to determine the presence of cancer and the type of cancer and not merely the presence of a certain hydroxylised peptide. It was even found that one was able to distinguish between a primary tumour and a secondary tumour.
  • a secondary tumour is a tumour that originates from another tumour by e.g. metastasis.
  • the present invention has shown to distinguish between a primary tumour in the liver, a hepatocellular carcinoma (HCC) and a metastatic tumour in the liver from colorectal cancer (CRLM).
  • HCC hepatocellular carcinoma
  • CRLM colorectal cancer
  • tumour and cancer are used interchangeably and refer both to uncontrolled growth of cells that may invade and intrude upon and destroy adjacent tissue and includes both malignant and benign tumours.
  • benign tumours are tumours that lack the ability to metastasize, although some tumours like glioma do not metastasize but are considered to be malignant.
  • Malignant tumours are able to metastasize and spread to other locations of the body via the lymph or blood system.
  • Hydroxylation is a process that introduces a hydroxyl group into an amino acid and is facilitated by enzymes called hydroxylases.
  • the principal residue to be hydroxylated in proteins is proline.
  • the hydroxylation occurs mostly at the ⁇ -C atom, forming hydroxyproline (Hyp).
  • Hyp hydroxyproline
  • proline may be
  • Lysine may also be hydroxylated on its ⁇ -C atom, forming hydroxylysine (Hyl). These reactions may be catalyzed by multi-subunit enzymes prolyl 4-hydroxylase, prolyl 3-hydroxylase and lysyl 5- hydroxylase, respectively. Also cysteine, phenylalanine, tyrosine are examples of amino acids that may be hydroxylated.
  • Hydroxylation pattern of a peptide may be measured by e.g. mass
  • spectrometry wherein the mass of a hydroxylated peptide is different from a non-hydroxylated peptide.
  • fragmentation of a hydroxylated peptide by e.g. MS-MS indentifies the position of the hydroxyl group, i.e. the hydroxylation pattern.
  • suitable methods to determine the hydroxylation pattern are any method that measures the interaction of any of the
  • hydroxylated peptides such as immuno assays, multiplex assays, competitive assays, beads, carrier chips, arrays, sticks, columns.
  • a suitable method may be immunoassay, multiplex assay, competitive assay and selection reaction monitoring (SRM).
  • SRM selection reaction monitoring
  • the detection may be indicated by any suitable means available such as chemiluminence and/or fluorescence.
  • the present invention is suitable for determining cancer in an organism.
  • an organism is a multicellular organism and preferably comprises a circulatory system such as a blood system and/or preferably comprises a digestive tract and/or preferably is motile.
  • animals are included in the term organism.
  • an organism is preferably a vertebrate, and/or a mammal, and most preferably a human.
  • a peptide is a polymer of amino acids linked by peptide bonds. They have the same peptide bonds as those in proteins, but are commonly shorter in length. The shortest peptides are dipeptides, consisting of two amino acids joined by a single peptide bond.
  • a peptide may be up to 1000 amino acids long, e.g. between 10 and 500 amino acids, preferably between 12 and 450 amino acids, more preferably between 15 and 400 amino acids, more preferably between 17 and 375 amino acids, more preferably between 20 and 350 amino acids, more preferably between 22 and 300 amino acids, more preferably between 25 and 250 amino acids, more preferably between 27 and 225 amino acids, more preferably between 30 and 200 amino acids, more preferably between 33 and 175 amino acids, more preferably between 35 and 150 amino acids, more preferably between 37 and 150 amino acids, more preferably between 40 and 125 amino acids, more preferably between 45 and 100 amino acids, more preferably between 50 and 85 amino acids, more preferably between 55 and 75 amino acids and most preferably between 60 and 70 amino acids.
  • Peptides have an amino end and a carboxyl end, unless they are cyclic peptides. It is to be understood that polypeptides, oligopeptides and even proteins are envisioned under the term peptides according to the present invention. In a preferred embodiment according to the invention and/or other
  • the peptides of the present invention are naturally occurring peptides.
  • Naturally occurring peptides are peptides that are formed by the organism itself, preferably formed without the addition of a pre-cursor to the organism. It is to be understood however that it is within the scope of the invention to add a precursor of the peptides of the invention prior to the method of the invention to increase the amount of peptides to be measured.
  • Amino acids as used herein are molecules containing an amine group, a carboxylic acid group and a side-chain that varies between different amino acids. Twenty-two amino acids are naturally incorporated into polypeptides and are called proteinogenic or natural amino acids. Of these, 20 are encoded by the universal genetic code. The remaining 2, selenocysteine (Sec, U) and pyrrolysine (Pyl, O), are incorporated into proteins by unique synthetic mechanisms.
  • the natural amino acids include Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic acid (Asp, D), Cysteine (Cys, C), Glutamic acid (Glu, E), Glutamine (Gin, Q), Glycine (Gly, G), Histidine (His, H), Isoleucine (He, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), Valine (Val, V).
  • the three and one letter code for the amino acids is given in parenthesis.
  • Non-standard amino acids that are found in proteins and/or peptides may be formed by post-translational modification, which is modification after translation during protein synthesis, e.g. hydroxylation.
  • the peptide is a collagen derived peptide.
  • Collagen is the most abundant protein in humans and is an important component of the extracellular matrix (ECM). So far, 29 types of collagen have been described. It is to be understood that the present invention encompasses peptides of all 29 types of collagen.
  • Preferred peptides are derived from collagen chosen from the group consisting of collagen type I, collagen type II, collagen type III, collagen type IV and collagen type V. Most preferred collagens are collagen type I, collagen type III.
  • the peptide has a mass of less than 20 kDa. More preferably the peptide has a mass of between 0.5 and 18 kDa, more preferably between 1 -15kDa, more preferably between 1.5-12 kDa, more preferably between 1.7 and 10, more preferably beteeen 2 and 8 and most preferably between 2.2 and 6 kDa.
  • the hydroxylation is on proline or lysine residues, most preferably on proline.
  • the hydroxylation pattern of at least 1 peptide is determined. More preferably the hydroxylation pattern of at least 2, more preferably of from 1-50, even more preferably from 3-40, more preferably from 4-30, more preferably from 5-25, more preferably from 6 to 20, more preferably from 7 to 15, more preferably from 8 to 12, and most preferably from 9-11 peptides the hydroxylation pattern is determined.
  • the biological sample is selected from the group consisting of whole blood, plasma, serum, urine, sputum, saliva, nipple aspirate, ductal lavage, vaginal fluid, nasal fluid, ear fluid, gastric fluid, cerebrospinal fluid, sweat, pericrevicular fluid, semen, prostatic fluid, faeces, cell lysate, tissue sample, biopsy, tissue lysate and tears.
  • the biological sample is selected from the group consisting of whole blood, plasma, serum, urine, sputum, saliva, nipple aspirate, vaginal fluid, gastric fluid, cerebrospinal fluid, semen, prostatic fluid, faeces, cell lysate, tissue sample, biopsy, and tissue lysate. More preferably the biological sample is selected from the group consisting of whole blood, plasma, serum, urine, sputum, saliva, cerebrospinal fluid, cell lysate, tissue sample, biopsy, and tissue lysate. Most preferably, the biological sample is selected from the group consisting of whole blood, plasma, serum, urine, tissue sample or tissue lysate.
  • Most suitable are urine, sputum, saliva, and faeces because no invasive procedure is needed to obtain such biological sample.
  • Most suitable biological sample is urine.
  • the biological sample is obtained from the organism. More preferably the method of the invention is conducted on the biological sample outside the organism.
  • the method according to the invention and/or embodiments described herein are directed to diagnosing of cancer.
  • cancer there are many types of cancer such as, breast cancer, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, brain cancer, cancer of the larynx, gallbladder cancer, pancreas cancer, rectum cancer, parathyroid cancer, thyroid cancer, adrenal cancer, neural tissue cancer, head and neck cancer, colon cancer, stomach cancer, bronchi cancer, kidney cancer, basal cell carcinoma, squamous cell carcinoma, metastatic skin carcinoma, osteo sarcoma, Ewin's sarcoma, vesticulum cell sarcoma, myeloma, giant cell tumor, small cell lung tumor, non-small-cell lung carcinoma, gallstones, islet cell tumor, primary brain tumor, acute and chronic lymphatic, and granulocytic tumors, hairy cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neurons, intestinal ganglion
  • rhabdomyosarcoma Kaposi's sarcoma, osteogenic and other sarcoma, malignant hypercalcemia, renal cell tumor, polycythermia vera,
  • the cancer is selected from the group consisting of colorectal liver metastases, hepatocellular carcinoma, adenoma, glioma and prostrate carcinoma.
  • a primary tumor HCC
  • a secondary tumor e.g. CRLM
  • HCC primary tumor
  • CRLM secondary tumor
  • the peptide is a peptide as depicted in table 1-3. More preferably the peptide is a peptide selected from the group consisting of SEQ ID 1-16. Also preferred are peptides with the mass as indicated in table 1- 3. In addition, preferred peptides are those peptides as depicted in table 1-3 which are 5-25% longer or shorter than the peptides as depicted in table 1-3, preferably 10-15% longer or shorted than the peptides as depicted in table 1-3. With longer and shorter is meant having 5-25%, 10-25% more or less amino acids.
  • the method according to the invention and/or other embodiments described herein is also suitable to monitor progress of cancer or to monitor effect of treatment of cancer.
  • a biological sample obtained at time 1 and a biological sample obtained at time 2 are measured and the hydroxylation pattern of a peptide is compared.
  • the peptide is a collagen peptide, and/or preferably the peptide is less than 20 kDa, and/or preferably the peptide is a peptide as depicted in table 1-3 and/or selected from the group consisting of SEQ ID 1-16.
  • the invention is also directed to a biomarker selected from the group consisting of SEQ ID 1-16.
  • the biomarker is used to detect or diagnose cancer, to monitor the progress of cancer or to monitor the effect of a treatment of cancer.
  • a biological sample obtained at time 1 and a biological sample obtained at time 2 are measured and the hydroxylation pattern of a peptide is compared.
  • a "threshold set" for the identification of markers specific for metastatic liver disease urine samples of 11 patients with diagnosed colorectal liver metastases (CRLM), 10 patients with hepatocellular carcinoma (HCC), 10 patients with benign liver adenomas, and 12 healthy controls were collected and stored at -85°C until workup. Prior to analysis by an Orbitrap mass spectrometer, 1 ml urine aliquots were filtered to remove masses higher than 20 kDa and subsequently desalted on a PD-10 column, lyophilized and dissolved in HPLC-grade water. Each sample was fractionated using nano-LC chromatography with a 90 minute gradient online coupled to a mass
  • MS spectra obtained from the threshold set were aligned using the vector- based Progenesis software package (Non-Linear Dynamics, New Castle UK). A total of 28380 different masses were detected and out of these masses, 2480 unique peptides could be identified in the Swissprot protein database using the Mascot search engine. Of these 2480 peptides, 1386 (55%) belonged to 26 different collagens. The second (verification) set provided 58545 masses with 3442 unique peptides identified. Out of these 3443 peptides, 1304 belonged to 34 different collagens. Univariate analysis of the threshold set revealed 43 collagen peptides that were significantly different (pO.01). Out of these 43, 7 were also significantly different in the verification set.
  • Hydroxylation pattern number corresponds with the amino acid in the peptide sequence and are indicated in either p (hydroxyproline) or k (hydroxylysine).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne le diagnostic et/ou le pronostic du cancer. Plus particulièrement, l'invention concerne le diagnostic et/ou le pronostic du cancer par la détermination du motif d'hydroxylation d'un peptide provenant d'un échantillon biologique provenant d'un organisme. La présente invention concerne également un procédé de surveillance de la progression du cancer ou de surveillance du traitement du cancer. La présente invention concerne également des biomarqueurs du cancer et leur utilisation.
PCT/NL2012/050406 2011-06-15 2012-06-11 Diagnostic du cancer Ceased WO2012173469A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12728843.9A EP2721055A1 (fr) 2011-06-15 2012-06-11 Diagnostic du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2011050432 2011-06-15
NLPCT/NL2011/050432 2011-06-15

Publications (1)

Publication Number Publication Date
WO2012173469A1 true WO2012173469A1 (fr) 2012-12-20

Family

ID=46321423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2012/050406 Ceased WO2012173469A1 (fr) 2011-06-15 2012-06-11 Diagnostic du cancer

Country Status (2)

Country Link
EP (1) EP2721055A1 (fr)
WO (1) WO2012173469A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021034196A1 (fr) * 2019-08-20 2021-02-25 Erasmus University Medical Center Rotterdam Biomarqueurs pour la détection du cancer du foie secondaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118522A1 (fr) * 2005-04-29 2006-11-09 Astrazeneca Ab Peptide
WO2010022210A2 (fr) * 2008-08-21 2010-02-25 Pxbiosciences Llc Diagnostic et surveillance de l’insuffisance rénale au moyen de biomarqueurs peptidiques
WO2010031822A1 (fr) 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Carcinome à cellules rénales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118522A1 (fr) * 2005-04-29 2006-11-09 Astrazeneca Ab Peptide
WO2010022210A2 (fr) * 2008-08-21 2010-02-25 Pxbiosciences Llc Diagnostic et surveillance de l’insuffisance rénale au moyen de biomarqueurs peptidiques
WO2010031822A1 (fr) 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Carcinome à cellules rénales

Also Published As

Publication number Publication date
EP2721055A1 (fr) 2014-04-23

Similar Documents

Publication Publication Date Title
US8841083B2 (en) PSA capture agents, compositions, methods and preparation thereof
US11793855B2 (en) TFPI inhibitors and methods of use
EP2118662A1 (fr) Marqueurs peptidiques pour le diagnostic de l'angiogenese
KR20200020927A (ko) 대장암을 검출하기 위한 바이오마커
CA2954051A1 (fr) Dosages srm pour cibles de chimiotherapie
Lukic et al. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis
US20110147218A1 (en) Soluble cadherin 17 for the diagnosis and risk stratification of cancer and tumor of the gastrointestinal tract
WO2012173469A1 (fr) Diagnostic du cancer
Dana et al. CD166 as a stem cell marker
KR101227434B1 (ko) 유방암 줄기세포 특이적 마커인 ｃｄ４４ 단백질 표적용 펩타이드 및 이의 이용
US20080319678A1 (en) Mass Tagging for Quantitative Analysis of Biomolecules using 13C Labeled Phenylisocyanate
EP2475685B1 (fr) Peptide monophosphorylé isolé de l'alpha-enolase humaine, utilisable pour la diagnose et la thérapie de l'adénocarcinome du pancréas, anticorps induits contre ledit peptide monophosphorylé ainsi que son utilisation
JP2008249587A (ja) カルモジュリンを標的とした腫瘍の判定方法
KR101297667B1 (ko) ｂｃｌ―２ 단백질 표적 펩타이드 및 이의 이용
Ogura et al. Proneurotensin/neuromedin N secreted from small cell lung carcinoma cell lines as a potential tumor marker
US20100203510A1 (en) Ppia marker for diagnosis of liver cancer and antibody, and screening method of compounds useful for inhibiting liver cancer
TWI483733B (zh) Ｔｆｐｉ抑制劑及使用方法
WO2016060382A1 (fr) Composition pour le diagnostic de cancer du pancréas, et procédé pour le diagnostic de cancer du pancréas à l'aide de cette dernière
Dumonceau et al. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis☆
CN109863405A (zh) 用于微管蛋白β-3链(TUBB3)蛋白的SRM/MRM测定
KR20080092490A (ko) 대장암 진단용 단백질 마커 켈그라눌린 ａ와 켈그라눌린 ｂ및 이들 각각에 대한 항체를 포함하는 대장암 진단키트
KR20130102690A (ko) 유방암 진단용 단백질 마커 탄산탈수효소 1, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12728843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012728843

Country of ref document: EP